IGC — what changed in the latest 10-Q
A section-by-section comparison of IGC's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +36 | −32 | ~19 | 18 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Text added/removed | +2 | −1 | ~1 | 9 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Our lead product candidate, IGC-AD1, is currently being evaluated in the CALMA, a randomized, double-blind, placebo-controlled Phase 2 clinical trial for the treatment of agitation in Alzheimer’s dementia, a neuropsychiatric condition affecting a substantial proportion of patients and associated wit…
IGC Pharma, a clinical-stage company developing treatments for Alzheimer’s disease, is committed to transforming patient care by striving to offer faster acting and more effective solutions. Our lead drug, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheim…
On June 30, 2026, Mr. Ram Mukunda, Chief Executive Officer, and Ms. Claudia Grimaldi, Principal Financial Officer, have purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at $0.27 per share, in lieu of and as consideration for the cancellation and satisfaction o…
● On June 23, 2026, the Company announced the beta version of its proprietary Agentic Harmonization Assistant (“AHA”), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer’s and aging-related datasets.
● On June 10, 2026, the Company announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia has reached the Company’s previously disclosed target enrollment of 146 patients, with 146 participants randomized at baseline.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
Our lead product candidate, IGC-AD1, is currently being evaluated in the CALMA clinical trial for the treatment of agitation in Alzheimer’s dementia, a neuropsychiatric condition affecting a substantial proportion of patients and associated with significant patient distress, caregiver burden, and he…
IGC Pharma, a clinical-stage company developing treatments for Alzheimer’s disease, is committed to transforming patient care by striving to offer faster acting and more effective solutions. Our lead drug, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheim…
●On March 30, 2026, the Company announced a strategic 12-part national media partnership with New to The Street, a leading financial media platform known for its integrated investor engagement and national television distribution. The collaboration is designed to enhance IGC Pharma’s visibility acro…
●On March 18, 2026, the Company announced that it will demonstrate its AHA, an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer’s & Parkinson’s Diseases Conference (“ADPD”) 2026. Participation in ADPD reflects the Com…
●On February 26, 2026, the Company today announced the filing of utility patent applications covering the architectural framework of its AHA, an internally developed AI-based data harmonization system.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-14
Our ability to advance IGC-AD1 depends on the successful execution and completion of our ongoing Phase 2 CALMA clinical trial. We may experience delays in patient enrollment, including failure to achieve targeted enrollment within expected timelines, or at all. Although target enrollment has been re…
Clinical trials are inherently complex and subject to numerous risks, including delays in site initiation, variability in site performance, patient recruitment challenges, protocol deviations, and unforeseen operational or logistical issues. Any such delays could increase development costs, extend t…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
Our ability to advance IGC-AD1 depends on the successful execution and completion of our ongoing Phase 2 CALMA clinical trial. We may experience delays in patient enrollment, including failure to achieve targeted enrollment within expected timelines, or at all. Clinical trials are inherently complex…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice